Literature DB >> 20566700

Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.

Richard D Press1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20566700      PMCID： PMC3228007          DOI： 10.1634/theoncologist.2010-0055

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  25 in total

Review 1.  Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Authors:  Ruibao Ren
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

Review 2.  How I monitor residual disease in chronic myeloid leukemia.

Authors:  Jerald P Radich
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

3.  Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Authors:  Ilaria Iacobucci; Giuseppe Saglio; Gianantonio Rosti; Nicoletta Testoni; Fabrizio Pane; Marilina Amabile; Angela Poerio; Simona Soverini; Simona Bassi; Daniela Cilloni; Renato Bassan; Massimo Breccia; Francesco Lauria; Barbara Izzo; Serena Merante; Francesco Frassoni; Stefania Paolini; Enrico Montefusco; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

4.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Authors:  Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus
Journal:  Blood       Date:  2009-09-24       Impact factor: 22.113

5.  Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.

Authors:  Richard D Press; Stephanie G Willis; Jennifer Laudadio; Michael J Mauro; Michael W N Deininger
Journal:  Blood       Date:  2009-07-22       Impact factor: 22.113

6.  Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.

Authors:  Hagop M Kantarjian; Jianqin Shan; Daniel Jones; Susan O'Brien; Mary Beth Rios; Elias Jabbour; Jorge Cortes
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

7.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

8.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

Review 9.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

10.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Authors:  Timothy Hughes; Giuseppe Saglio; Susan Branford; Simona Soverini; Dong-Wook Kim; Martin C Müller; Giovanni Martinelli; Jorge Cortes; Lan Beppu; Enrico Gottardi; Dongho Kim; Philipp Erben; Yaping Shou; Ariful Haque; Neil Gallagher; Jerald Radich; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544
View more
  2 in total

1.  Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.

Authors:  Katherine A Yeager; Drenna Waldrop-Valverde; Sudeshna Paul; Deborah Watkins Bruner; Rebecca Klisovic; Emily Burns; Tamara A Mason; Nisha Patel; Bonnie Mowinski Jennings
Journal:  Res Nurs Health       Date:  2020-08-31       Impact factor: 2.228

2.  Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study.

Authors:  Hyunkyung Park; Dong-Yeop Shin; Inho Kim; Sang-Kyun Sohn; Youngil Koh; Je-Hwan Lee; Kyoo-Hyung Lee; Dae-Young Kim; Hyeong-Joon Kim; Jae-Sook Ahn; Jeong-Ok Lee; Soo-Mee Bang; June-Won Cheong; Sang-Gon Park; Seonyang Park; Yoo Jin Lee; Seo-Yeon Ahn
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.